Get the Stockscreener App
56.75
1.01%
0.57
Hologic Inc stock is traded at $56.75, with a volume of 3.25M.
It is up +1.01% in the last 24 hours and down -4.32% over the past month.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
See More
Previous Close:
$56.18
Open:
$56.3
24h Volume:
3.25M
Relative Volume:
1.05
Market Cap:
$12.07B
Revenue:
$4.03B
Net Income/Loss:
$789.50M
P/E Ratio:
17.04
EPS:
3.33
Net Cash Flow:
$1.15B
1W Performance:
+4.78%
1M Performance:
-4.32%
6M Performance:
-27.95%
1Y Performance:
-25.08%
1-Day Range:
$55.97
$56.82
1-Week Range:
$51.90
$57.51
52-Week Range:
$51.90
$84.67
Hologic Inc Stock (HOLX) Company Profile
Name
Hologic Inc
Sector
Industry
Phone
(508) 263-2900
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
56.75 | 12.07B | 4.03B | 789.50M | 1.15B | 3.33 |
|
ISRG
Intuitive Surgical Inc
|
536.51 | 189.75B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
95.75 | 48.62B | 9.91B | 1.02B | 665.00M | 2.05 |
|
BDX
Becton Dickinson Co
|
167.22 | 48.37B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
245.04 | 35.18B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
82.27 | 16.46B | 3.90B | 392.30M | 288.10M | 1.95 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-25 | Downgrade | Argus | Buy → Hold |
| Feb-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-03-25 | Downgrade | Needham | Buy → Hold |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Dec-10-24 | Reiterated | Needham | Buy |
| Oct-01-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-24 | Initiated | Stephens | Overweight |
| Apr-03-24 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-23 | Upgrade | Needham | Hold → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Oct-14-21 | Initiated | Redburn | Neutral |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-20-20 | Downgrade | Needham | Buy → Hold |
| Nov-05-20 | Reiterated | Needham | Buy |
| Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-30-20 | Reiterated | Needham | Buy |
| Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Jan-31-19 | Reiterated | Needham | Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-09-18 | Initiated | UBS | Neutral |
| Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic Inc Stock (HOLX) Latest News
Director Makes Bold Move with Major Hologic Stock Purchase - TipRanks
Hologic's (NASDAQ:HOLX) Solid Earnings Are Supported By Other Strong Factors - Yahoo Finance
Unlocking the Gonorrhea Diagnostic Market: Future Demand, Top - openPR.com
HPV and Pap Testing Market Grows Amid Cervical Cancer Screening Awareness | Roche, Hologic, Qiagen - openPR.com
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know - MSN
Hologic: Soft Performance, But Cheap Enough (NASDAQ:HOLX) - Seeking Alpha
Mizuho cuts Hologic stock price target to $65 from $75 - Investing.com Australia
Hologic outlines Q3 2025 revenue target of $1B-$1.01B amid breast health recovery - MSN
Four Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries - AboutLawsuits.com
Mizuho cuts Hologic stock price target to $65 from $75 By Investing.com - Investing.com South Africa
Myomectomy Market Strengthens with Rise in Uterine Fibroid - openPR.com
BioZorb Lawsuit LawyerBreast Biopsy Marker RecallApril 2025 Update - Levin Papantonio
Hologic (HOLX) Faces Lower Price Target Amidst Maintained Rating | HOLX Stock News - GuruFocus
Lobbying Update: $210,000 of HOLOGIC INC. lobbying was just disclosed - Nasdaq
Hologic (HOLX) Price Target Reduced by Morgan Stanley Analyst | HOLX Stock News - GuruFocus
Morgan Stanley Cuts Price Target on Hologic to $65 From $77, Keeps Equalweight Rating - marketscreener.com
Hologic drops as tariffs and geopolitics lead to guidance cut - MSN
Hologic Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
Hologic, Inc. (NASDAQ:HOLX) Q2 2025 Earnings Call Transcript - Insider Monkey
Hologic stock price target cut to $65 by Jefferies - Investing.com South Africa
Breaking Down Hologic: 10 Analysts Share Their Views - Benzinga
Hologic Inc. stock underperforms Friday when compared to competitors - MarketWatch
Hologic (HOLX) Price Target Lowered by RBC Capital | HOLX Stock News - GuruFocus
Hologic (HOLX) Target Price Lowered by Raymond James | HOLX Stock News - GuruFocus
Hologic sees drop in sales and tariff impact on stock price - Radiology Business
Leerink Partners Adjusts Hologic Price Target to $60 From $65 - marketscreener.com
Jefferies Adjusts Hologic Price Target to $65 From $78 - marketscreener.com
Hologic Enters Oversold Territory (HOLX) - Nasdaq
Hologic falls after 2025 profit forecast cut - TradingView
Hologic (HOLX) Shares Plunge 18% After Revised Earnings Outlook - GuruFocus
Evercore ISI Group Lowers Price Target for Hologic (HOLX) to $62 - GuruFocus
Evercore ISI Group Lowers Price Target for Hologic (HOLX) to $62 | HOLX Stock News - GuruFocus
Hologic (HOLX): Price Target Reduced Amid Tariff Pressures | HOL - GuruFocus
Hologic (HOLX): Price Target Reduced Amid Tariff Pressures | HOLX Stock News - GuruFocus
RBC Cuts Price Target on Hologic to $70 From $75, Keeps Sector Perform Rating - marketscreener.com
Hologic (HOLX) Receives Hold Rating from Needham Analyst | HOLX Stock News - GuruFocus
Hologic stock drops after guidance cut (HOLX:NASDAQ) - Seeking Alpha
HOLOGIC INC SEC 10-Q Report - TradingView
Hologic Q2 Earnings & Revenues Top, '25 EPS View Lowered, Stock Down - Yahoo Finance
Hologic Inc (HOLX) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth - Yahoo Finance
Hologic shares fall 3% as Q2 guidance disappoints By Investing.com - Investing.com Nigeria
Hologic Inc (HOLX) Q2 Earnings: Revenue Hits $1,005.3M, Non-GAAP EPS at $1.03, Surpassing Estimates - GuruFocus
Hologic Exceeds Revenue Guidance Amid Challenges - TipRanks
Hologic: Fiscal Q2 Earnings Snapshot - MySA
Hologic Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Hologic Q2’25 slides: Mixed results amid long-term growth strategy - Investing.com India
Earnings call transcript: Hologic beats Q1 2025 EPS forecast amid stock dip - Investing.com Nigeria
Medical equipment maker Hologic lowers annual profit forecast on tariff uncertainty - TradingView
Hologic Posts Q2 Loss On Impairment Charges Despite Stable Revenue - Nasdaq
Hologic Announces Financial Results for Second Quarter of Fiscal 2025 - BioSpace
Hologic beats Q2 estimates, lowers full-year outlook By Investing.com - Investing.com South Africa
Hologic Inc Stock (HOLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.40%
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):